Physician profile
Robert A Kolarczyk
NPI 1922035559
$2,854.82
in general payments reported to CMS, 2019-2025
15 companies · $299 in 2025
The $299 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $597 · 2020: $112 · 2021: $217 · 2022: $732 · 2023: $574 · 2024: $325 · 2025: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,197.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $339.78 | 2022-2025 | Centurion |
| Regeneron Healthcare Solutions, INC. | $335.14 | 2019-2023 | Eylea |
| Bausch & Lomb Americas INC. | $324.12 | 2023-2024 | Miebo, Xiidra |
| New World Medical,INC. | $297.50 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $292.99 | 2022-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $236.32 | 2019-2020 | |
| Glaukos Corporation | $131.99 | 2019 | |
| Biogen, INC. | $130.24 | 2023 | |
| Horizon Therapeutics Plc | $124.48 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $123.35 | 2022 | |
| Dompe US, INC. | $111.04 | 2024 | Oxervate |
| Amgen INC. | $109.54 | 2024 | Tepezza |
| Apellis Pharmaceuticals, INC. | $103.27 | 2023 | Syfovre |
| Aerie Pharmaceuticals, INC. | $102.23 | 2019 | |
| Allergan, INC. | $92.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Kolarczyk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.